Astex uses its fragment based drug discovery technology to identify and develop new medicines, primarily for the treatment of cancer and antiviral diseases. The company has a number of internally developed therapeutic candidates in clinical trials. Astex merged with SuperGen in July 2011 and was acquired by Otsuka Pharma for $860 million in September 2013.
Location: United Kingdom, England, Cambridge
Employees: 51-200
Total raised: $150K
Founded date: 1999
Investors 2
| Date | Name | Website |
| - | Industry V... | industryve... |
| - | Abingworth... | abingworth... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.05.2022 | - | $150K | - |
Mentions in press and media 10
| Date | Title | Description |
| 21.10.2024 | Astex Pharmaceuticals Announce Key Data Presentations at the 36th EORTC-NCI-AACR Symposium | CAMBRIDGE, United Kingdom, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, a pharmaceutical company based in Cambridge, UK, dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases o... |
| 18.06.2024 | Update on CAPItello-290 Phase III trial | Update on CAPItello-290 Phase III trial Tue, Jun 18, 2024 08:00 CET Report this content 18 June 2024 Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer The CAPIte... |
| 31.12.2022 | Astex Co-founder and CEO Harren Jhoti Awarded OBE in the King's New Year Honours | CAMBRIDGE, United Kingdom, Dec. 31, 2022 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, UK, congratulates Harren Jhoti, PhD, FRS, FMedSci, its co-founder, President and CEO on being honoured in the 2023 King's New Year Honours list. Dr. Jhoti h... |
| 31.12.2022 | Astex Co-founder and CEO Harren Jhoti Awarded OBE in the King’s New Year Honours | /EIN News/ -- CAMBRIDGE, United Kingdom, Dec. 31, 2022 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, UK, congratulates Harren Jhoti, PhD, FRS, FMedSci, its co-founder, President and CEO on being honoured in the 2023 King’s New Year Honours lis... |
| 13.01.2021 | Taiho and Astex extend strategic oncology collaboration with MSD | Taiho and Astex extend strategic oncology collaboration with MSD 13-01-2021 Taiho Pharmaceutical Co, Ltd. announces that it and Astex Pharmaceuticals (UK), both Otsuka group companies, have granted an exclusive licence under their joint, sm... |
| 08.07.2019 | LeadXpro to collaborate with a British drug discovery company | |
| 07.06.2019 | Astex Pharmaceuticals and Otsuka announce results of latest study | Astex Pharmaceuticals and Otsuka announce results of latest study 07-06-2019 Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASCERTAIN study of the novel oral cedazuridine and decitabine fixed-dose combination (ASTX727) in ... |
| 16.03.2018 | Astex continues to deliver in oncology | Astex continues to deliver in oncology 16-03-2018 Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, annou... |
| 21.11.2016 | Astex Pharmaceuticals Makes Strategic Investment in Dementia Discovery Fund | Astex Pharmaceuticals, a Cambridge, England, UK-based pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system (CNS), has become a strateg... |
| 12.10.2015 | Dementia Consortium signs new pharma partner Astex Pharmaceuticals | Dementia Consortium signs new pharma partner Astex Pharmaceuticals 12-10-2015 The Dementia Consortium, a unique charity-private partnership, today announced Astex Pharmaceuticals as a new member. The Consortium is a £3.5m cross-sector drug ... |